je.st
news
Ziarco Pharma Ltd - Phase 2a Psoriasis Study Initiated With Ziarco's Lead Compound ZPL-389
2016-02-03 02:06:37| drugdiscoveryonline Home Page
Ziarco Pharma Ltd., a biopharmaceutical company focusing on the development of novel drugs against inflammatory skin disorders, recently announced that dosing has started in a Phase 2a proof of concept study in moderate to severe psoriasis with ZPL-389
Tags: study
lead
phase
initiated
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||